Maurizio Scaltriti

机构：AstraZeneca (Japan), AstraZeneca (United States) · ORCID：0000-0002-5522-1447

发表论文 677 篇 · 总被引 26653 次 · h-index 75

代表论文

• Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study (2026 · Journal of Clinical Oncology · 被引 2)
• The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer (2025 · Cancer Research · 被引 2)
• Comprehensive cellular analysis with single-nucleus RNA-seq of archived PAXgene whole blood samples (2026 · Cell Reports Methods · 被引 1)
• Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer (2026 · medRxiv)
• Abstract 5546: Rilvegostomig elicits greater immune activation and tumor inhibition than clinically approved anti-PD-1 monotherapy in models of HNSCC (2026 · Cancer Research)
• Abstract 3226: FOXA1 alterations drive endocrine therapy resistance through unique transcriptional and epigenomic programs in breast cancer (2026 · Cancer Research)